Virtual Library

Start Your Search

Q. Chang



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      61P - mir-125b plays a tumor suppressor role in inflammation-related non-small cell lung cancer via repressing IGF-1 signal pathway (ID 509)

      12:30 - 13:00  |  Author(s): Q. Chang

      • Abstract

      Background:
      Epidemiologic data have indicated that chronic inflammation was highly associated with the pathogenesis of lung cancer. However, the molecular relations between inflammation and lung cancer have not been well understood. MicroRNAs could connect the inflammatory response with tumorigenesis through regulating their cancer-related targets. The aim of the present study was to identify the core miRNA in inflammation-related lung cancer and its potential mechanisms.

      Methods:
      RT-PCR was used to detect the expression of miRNAs and mRNAs. CKK8 and flow cytometry assays was performed for the function experiments. Microarray analysis and IPA analysis were used to predict the potential signal pathway.

      Results:
      Mir-125b was the most dramatically up-regulated miRNAs after treated with IFN-r, whereas after stimulated with IL-10, mir-125b was the most strikingly down-regulated ones. Restoration of mir-125b expression could completely overrode the impact of IL-10 on both cell proliferation and apoptosis in NSCLC cell lines. And the level of mir-125b was significantly lower in 30 NSCLC tumor tissues compared with normal controls (P < 0.0001). Microarray analysis found 69 up-regulated genes and 105 down-regulated genes after down-regulate mir-125b. And IPA analysis indicated that IGF-1 signaling pathway was dramatically activated. The results were validated by RT-PCR.

      Conclusions:
      MiR-125b might play a tumor suppressor role via inhibiting IGF-1 signaling in inflammation-related lung cancer.

      Clinical trial identification:


      Legal entity responsible for the study:
      Yanwei Zhang

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.

    • +

      92P - Expression of TNFRII in serum is correlated with the significant risk of subcentimeter lung adenocarcinoma (ID 312)

      12:30 - 13:00  |  Author(s): Q. Chang

      • Abstract

      Background:
      With the rapid advances of LDCT screening for lung cancer, the opportunity to detect subcentimeter NSCLC is gradually increasing. But, even subcentimeter NSCLCs are not always in the early stage. Thus, it is quite important for us to judge the possibility of malignancy for these patients, even the tumor size is less than 10 mm. Chronic inflammation is well established as a hallmark in lung carcinogenesis. The aim of the present study is to evaluate the correlation between inflammation biomarkers and the risk for subcentimeter lung adenocarcinoma.

      Methods:
      Inflammatory biomarkers were measured in 71 subcentimeter lung adenocarcinoma patients and 71 age-, sex- and smoking-matched healthy controls by using the Luminex bead-based assay.

      Results:
      The expression level of TNFRII is significantly down-regulated in subcentimeter lung adenocarcinoma patients compared with the healthy controls (P < 0.001). And the results were validated by oncomine data mining analysis. Elevated levels of TNFRII were associated with an 89% reduced risk for subcentimeter lung adenocarcinoma. (OR = 0.11, 95% CI: 0.04–0.30, P = 2.4 × 10[−5]). BLC was associated with a 2.70-fold (95% CI: 1.31–5.58, P = 7.0 × 10[−3]) increased risk of subcentimeter lung adenocarcinoma for the comparison of patients in the higher-level group with the lower-level group. To yield more information, the BLC/TNFRII ratio was created to examine their prediction for the risk of subcentimeter lung adenocarcinoma, and there was a 35-fold increased risk for patients in the higher-level group relative to patients in the lower-level group. Further ROC curve analysis revealed that TNFRII was a significant diagnostic biomarker for subcentimeter lung adenocarcinoma, with the area under the curve of 0.73 (95% CI: 0.65–0.82, P = 2.0 × 10[−6]). The sensitivity, specificity and accuracy were 0.75, 0.72 and 0.73, respectively.

      Conclusions:
      Our findings demonstrated that TNFRII was associated with the significant risk of subcentimeter lung adenocarcinoma and could be a promising biomarker for accessorily diagnosing subcentimeter lung adenocarcinoma.

      Clinical trial identification:


      Legal entity responsible for the study:
      Yanwei Zhang

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.